Sinovac says its Covid-19 vaccine more effective with longer dosing interval


A health worker shows the Sinovac vaccine against the Covid-19 coronavirus at a community health centre in Lambaro, Indonesia's Aceh province on Monday (Jan 18, 2021). - AFP

BEIJING, Jan 18 (Reuters): China's Sinovac Biotech said on Monday that a clinical trial in Brazil showed its Covid-19 vaccine was almost 20 percentage points more effective in a small sub-group of patients who received their two doses longer apart.

The protection rate for 1,394 participants who received doses of either CoronaVac or placebo three weeks apart was nearly 70%, a Sinovac spokesman said.

Brazilian researchers announced last week that the vaccine's overall efficacy was 50.4% based on results from more than 9,000 volunteers, most of whom received doses 14 days apart, as outlined in the trial protocol.

The spokesman said a small number of participants received their second shot late due to a various reasons, without elaborating.

The dosing interval for Covid-19 vaccines has become a hot topic of debate among scientists, regulators and governments.



UK regulators have said a Covid-19 vaccine from AstraZeneca and Oxford University is more effective when there is a longer gap between doses than initially envisaged.

Britain has also decided to allow a longer gap between doses of a Covid-19 vaccine from Pfizer and BioNTech , even though the companies say they only have efficacy data for a shorter period between shots.

The Sinovac spokesman cautioned the robustness of the data from the sub-group was weaker than the 50% result, which is based on the combined data of those receiving doses two or three weeks apart.

While Sinovac's researchers had said early stage trials showed a four-week interval induced the stronger antibody response than two weeks, this is the first time the company has released efficacy data from a Phase III trial with dosing patterns that differ from its trial protocol.

Sinovac has yet to release global results of its Phase III trials, but its Covid-19 vaccine has been approved for emergency use in several countries, including Brazil, Indonesia and Turkey. - Reuters
Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

84% readers found this article insightful

Next In Aseanplus News

Cambodian PM orders temporary closure of civil institutions as Covid-19 cases rise
Brunei: Only four active Covid-19 cases remaining in the country; one more recovery reported
Thailand places helmeted hornbills under protection
Sino-US cooperation on Covid-19 critical: China Daily editorial
China state funds buy stocks to stem worsening rout
Laos, Pakistan and Belarus diplomats in Geneva express support for China on Hong Kong affairs
Asia markets swing as rate hike fears offset reflation trade
China aims to complete the construction of 5G network in 5 years: minister
China’s ‘two sessions’: key takeaways from the annual government work report
Vietnamese adopt healthier, sustainable lifestyle choices: report

Stories You'll Enjoy


Vouchers